StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Reported (IFRS) SG&A expense by Quarter

Reported (IFRS) SG&A expense ($M) ($M)

QuarterlyAnnual

AstraZeneca Reported (IFRS) SG&A expense: -$5,651M in Q2 2026, up 16.2% from a year earlier. That is the lowest of the 27 quarters on record here.

Latest, Q2 2026
-5,651
Period ended Jun 30, 2026
Change on a year earlier
+16.2%
-4,864 in Q2 2025
History
27 quarters
Since Q2 2017
Sources
26
Documents cited below

Where the Q2 2026 figure comes from

“|| SG&A expense | | (5,651) | | | 72 | | | 1,183 | | 346 | | (4,050) | 7 | 4”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Consolidated Income Statement.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReported (IFRS) SG&A expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-5,651+16.2%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-4,920+9.5%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-5,492+1.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-5,085-1.1%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-4,864-1.3%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-4,492-0.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-5,410+0.7%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-5,143+7.1%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-4,929-1.1%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-4,495+10.7%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-5,371+16.2%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-4,800+12.2%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-4,986+6.5%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-4,059-16.1%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-4,621-9.7%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-4,277+4.6%Form 6-K FY2022Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Reported (IFRS) SG&A expense ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/rep-sga-cmp

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.